Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Scopolamine pharmacokinetics and EEG effects in healthy volunteers
ACTRN12622000228785Phase 4Terminated
- Sponsor
- The University of Auckland
- Start
- Jun 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of scopolamine in major depressive disorder (MDD), sponsored by The University of Auckland. Primary endpoint: Power spectral density of the eyes-open EEG. Started Jun 2021; status: terminated.
02
Drugs
scopolamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ACTRN12622000228785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000228785.